W
WAVEMAN · COMPANY
BLSM · Blossomhill Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

BLSM

BlossomHill Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001839970
CLUSTER · 6 INSIDERSACTIVIST 13DC-SUITE BUYING · 2☆ WATCH
INSIDER NET · 180D
$25.2M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
6
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
14
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$25.2M over 180 days
+$25.2M over 90 days · +$5.0M of it by a 10%+ holder
more than 97% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
6 insiders independently bought a net $25.2M — no planned sales are queued against it.
ORBIMED ADVISORS LLC disclosed a 5%+ stake (8.9%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +37.6%
+37.6%12M
-1%+12%+25%+38%2026-082026-082026-082026-082026-082026-082026-09 2026-08-10 · ORBIMED ADVISORS LLC bought $10.0M2026-08-10 · GORDON CARL L bought $10.0M2026-08-10 · Chen Bihua bought $5.0M2026-08-10 · Schmid John P. bought $96.0K2026-08-07 · Liptak Vincent Paul bought $39.5K2026-08-10 · Liptak Vincent Paul bought $35.2K2026-08-10 · Keyes Jason A bought $11.2K2026-08-18 · ORBIMED ADVISORS LLC filed a 5%+ stake (8.9%)2026-08-18 · OrbiMed Capital GP VIII LLC filed a 5%+ stake (8.9%)2026-08-13 · Cormorant Global Healthcare Master Fund, LP filed a 5%+ stake (3.13%)2026-08-13 · Cormorant Global Healthcare GP, LLC filed a 5%+ stake (3.13%)2026-08-13 · Cormorant Private Healthcare Fund III, LP filed a 5%+ stake (4.01%)2026-08-13 · Cormorant Private Healthcare GP III, LLC filed a 5%+ stake (4.01%)2026-08-13 · Cormorant Private Healthcare Fund V, LP filed a 5%+ stake (3.43%)2026-08-13 · Cormorant Private Healthcare GP V, LLC filed a 5%+ stake (3.43%)2026-08-13 · Cormorant Private Healthcare Fund VI, LP filed a 5%+ stake (1.22%)2026-08-13 · Cormorant Private Healthcare GP VI, LLC filed a 5%+ stake (1.22%)2026-08-13 · Cormorant Asset Management, LP filed a 5%+ stake (11.79%)2026-08-13 · Chen Bihua filed a 5%+ stake (11.8%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
6 insiders reported buying shares.
The record shows a net $25.2M bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BlossomHill Therapeutics, Inc. insiders bought a net $25.2M of stock across 7 Form 4 purchases and sales, with 6 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Liptak Vincent Paul
General Counsel
BUY
2026-08-10
2,200.0
$35.2K
Keyes Jason A
Chief Financial Officer
BUY
2026-08-10
700.0
$11.2K
Chen Bihua
Director
BUY
2026-08-10
312,500.0
$5.0M
Schmid John P.
Director
BUY
2026-08-10
6,000.0
$96.0K
ORBIMED ADVISORS LLC
Director
BUY
2026-08-10
625,000.0
$10.0M
7 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 2 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

5%+ owners
13D = intent to influence · 13G = passive
ORBIMED ADVISORS LLC
ACTIVIST 13D · 2026-08-18
8.9%
OrbiMed Capital GP VIII LLC
ACTIVIST 13D · 2026-08-18
8.9%
Cormorant Global Healthcare Master Fund, LP
ACTIVIST 13D · 2026-08-13
3.13%
Cormorant Global Healthcare GP, LLC
ACTIVIST 13D · 2026-08-13
3.13%
Cormorant Private Healthcare Fund III, LP
ACTIVIST 13D · 2026-08-13
4.01%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 2 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
1
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →